New hope for HLH patients: targeted drug tested in clinical trial
NCT ID NCT07339345
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called golidocitinib for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the body. The trial will include 28 people aged 14 to 70 with newly diagnosed or returning HLH. The goal is to see if the drug can improve blood markers and symptoms, and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••